Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: Validation studies in patients with lung cancer

Journal of Nuclear Medicine

Volumn 46, Issue 2, 2005, Pages 274-282

  Muzi, Mark ^a,c   Vesselle, Hubert ^a   Grierson, John R ^a   Mankoff, David A ^a   Schmidt, Rodney A ^b   Peterson, Lanell ^a   Wells, Joanne M ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

3 deoxy 3 fluorothymidine; Cell proliferation; Ki 67; Kinetic modeling; Thymidine kinase 1

Indexed keywords

3' FLUOROTHYMIDINE; KI 67 ANTIGEN; THYMIDINE KINASE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE MARROW; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMAGING; IMMUNOHISTOCHEMISTRY; KINETICS; LUNG CANCER; MATHEMATICAL ANALYSIS; MUSCLE; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; VALIDATION STUDY; ALGORITHM; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; ISOTOPE DILUTION ASSAY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; DIDEOXYNUCLEOSIDES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN SPECIFICITY; RADIOISOTOPE DILUTION TECHNIQUE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 15844427289     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71-88.
2. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;41(suppl):96S-103S.
3. Cleaver JE. The relationship between the rate of DNA synthesis and its inhibition by ultraviolet light in mammalian cells. Radiat Res. 1967;30:795-810.
4. Christman D, Crawford FJ, Friedkin M, Wolf A. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11 C)thymidine. Proc Natl Acad Sci USA. 1972;69:988-992.
5. 3H]thymidine uptake in rodent and canine neoplasms-concise communication. J Nucl Med. 1981;22:869-874.
6. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med. 1984;25: 759-764.
7. Eary JF, Mankoff DA, Spence AM, O'Sullivan F, Krohn KA. Quantitation of brain tumor proliferation with C-11 thymidine PET imaging [abstract]. J Nucl Med. 1998;39(suppl):201P.
8. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
9. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[C-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043-1055.
10. 11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging. 2002;1:145-150.
11. Goethals P, van Eijkeren M, Lodewyck W, Dams R. Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors. J Nucl Med. 1995;36:880-882.
12. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17-22.
13. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-1217.
14. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032.
15. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
16. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8: 3315-3323.
17. 18F]FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
18. 18F]-FDG. J Nucl Med. 2003;44:1426-1431.
19. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
20. Sundseth R, Joyner SS, Moore JT, Domsife RE, Dev IK. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother. 1996; 40:331-335.
21. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine (FLT) in proliferating A549 cells: validations for positron emission tomography (PET). Nucl Med Biol. 2004;31:829-837.
22. 18F]- Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482-1488.
23. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
24. Starborg M, Gell K, Brundell E, Hoog C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci. 1996;109:143-153.
25. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407-1412.
26. 18F]-FDG PET. J Nucl Med. 2004;45:226-231.
27. Muzi M, Mankoff DA, Grierson JR, et al. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46: 371-380.
28. Pugsley JM, Schmidt RA, Vesselle H. The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J. 2002;8:222-233.
29. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27: 143-156.
30. Lewellen TK, Kohlmyer SG, Miyaoka RS, et al. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci. 1996;43:2199-2206.
31. Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4:489-498.
32. Shields AF, Mankoff DA, Graham MM, et al. Analysis of 2-[C-11]-thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290-296.
33. Kohlmyer SG, Vesselle H, Miyaoka RS, Kaplan MS, Lewellen TK. Comparison of recovery coefficients for PET based on maximum and average ROI pixel values [abstract]. Eur J Nucl Med. 2000;27:1027.
34. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med. 1996;37:2049-2057.
35. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
36. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
37. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
38. O'Sullivan F. Metabolic images from dynamic positron emission tomography studies. Stat Methods Med Res. 1994;3:87-101.
39. Akaike H. Data analysis by statistical models. No To Hattatsu. 1992;24:127-133.
40. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med. 1998;39:440-448.